Introduction {#s1}
============

Anaphylaxis is a non-homogeneous clinical diagnosis, depending on various triggering and augmenting factors ([@B1]). This variability introduces a wide range of possible reaction-symptom severities. Therefore, multiple subtypes of anaphylaxis have been previously identified (i.e., food-dependent exercise-induced anaphylaxis, venom anaphylaxis, biphasic anaphylaxis).

The mainstay of anaphylaxis management is the intramuscular dose of adrenaline ([@B2]), but in the most severe cases of anaphylaxis, it might be insufficient to restore a stable patient status. Refractory anaphylaxis (although the established definition is lacking) might be defined as anaphylaxis meeting the criteria by NIAID/FAAN ([@B3]) which, after the treatment with at least two doses of minimum 300 μg adrenaline, does not achieve normalization of the clinical symptoms in a given individual. Common elicitors and symptoms of refractory anaphylaxis, as well as the therapeutic strategy for the most severe cases, differ from the usual reactions ([@B4]) and call for specific research and targeted guideline development for refractory anaphylaxis cases.

We aimed to distinguish the prevalence of refractory anaphylaxis among anaphylaxis cases and to describe symptoms and factors which may increase the risk of a refractory anaphylaxis episode.

Methods {#s2}
=======

The European Anaphylaxis Registry \[described in detail elsewhere ([@B5])\] provided data for this analysis (status from March 2018). We selected cases where patients received at least two doses of adrenaline and failed to recover adequately and assigned them to the "refractory anaphylaxis group." The flowchart in [Figure 1](#F1){ref-type="fig"} represents the detailed case-selection process.

![Flowchart illustrating the cases selection process for the final database.](fimmu-10-02482-g0001){#F1}

The final database consisted of 42 cases of refractory anaphylaxis from 7 countries: Germany: 19, Switzerland: 11, France: 6, Austria: 2, Poland: 2, Spain: 1, Ireland: 1. We compared these to a group of severe, non-refractory cases of anaphylaxis. Severe reactions were identified based on the definition by NIAID/FAAN ([@B3]) and presented with significant hypoxia, hypotension, confusion, collapse and loss of consciousness, or incontinence. We compared the frequency of various elicitors, symptoms, and factors known to increase the risk of severe anaphylaxis ([@B6]) in both groups as well as their management.

We performed a statistical analysis in the R Statistical Package ([@B7]). A simple comparison of categorical variables was performed using Fisher\'s exact test; continuous variables were analyzed using the Mann-Whitney *U*-test. We defined statistical significance as α = 0.05. Data, along with the analysis script, can be accessed at [www.github.com/wolass/RefractoryAnaOrg](http://www.github.com/wolass/RefractoryAnaOrg).

Results {#s3}
=======

Refractory Anaphylaxis Accounts for Less Than 0.5% of Severe Anaphylaxis Cases in the Register
----------------------------------------------------------------------------------------------

The European Anaphylaxis Registry captured 42 cases of refractory anaphylaxis and 4,820 severe, non-refractory anaphylaxis. The frequency of refractory anaphylaxis was 0.37% of all anaphylaxis cases reported in the registry. Each year \~1% (0.853% ± 0.765%) of severe anaphylactic episodes are refractory to treatment with adrenaline. When considering patients who experienced anaphylaxis in a perioperative setting or a medical facility, nearly 3.72% patients present with reactions that do not respond to adrenaline vs. 0.448% in non-medical setting (9.3 times more).

Increased Frequency of Previous Reactions in Patients With Refractory Anaphylaxis
---------------------------------------------------------------------------------

The mean age at the reaction was 41.4 ± 20.8 years, which did not differ from severe, non-refractory cases, *p* = 0.897). The percentage of males within the refractory anaphylaxis group was 50%. More patients suffered from a concomitant malignant disease in the refractory anaphylaxis group. Most strikingly, patients with refractory reactions more often had a previous anaphylactic reaction in their medical history (*p* = 0.0336). Baseline tryptase levels were significantly higher in the refractory anaphylaxis group as 7 refractory patients (16.7%) had tryptase level above 11.5 μg/L (vs. 7.8%). The demographic summary of refractory cases is shown in [Table 1](#T1){ref-type="table"}.

###### 

Summary of the refractory anaphylaxis cases.

  **Sex**   **Group**    ***n***   **Age**   **Cardiologic**   **DM**   **Food allergy**   **Mastocytosis**   **Malignancy**   **Atopic dermatitis**   **Tryptase \[median\]**
  --------- ------------ --------- --------- ----------------- -------- ------------------ ------------------ ---------------- ----------------------- -------------------------
  Female    Refractory   22        40.0      31.82             9.09     13.64              9.09               0.00             18.18                   5.22
  Male      Refractory   20        43.0      30.00             15.00    5.00               5.00               15.00            5.00                    7.43
  Female    Severe       2421      43.4      20.57             2.27     5.37               2.56               2.19             6.73                    4.30
  Male      Severe       2399      40.2      22.89             3.58     5.84               2.54               2.08             6.25                    4.72
            *p*-value    0.78      0.9       0.19              0.07     1.00               0.10               0.07             0.20                    0.01

*Age is represented by a mean value, other variables as fractions \[%\]. DM, diabetes mellitus, p-value is derived from a Mann-Whitney U-test or a Chi^2^ test for interval and categorical variables, respectively. Refractory group was compared to severe anaphylaxis cases without differentiating into male and female subgroups*.

Drugs Are the Most Frequent Elicitors of Refractory Anaphylaxis
---------------------------------------------------------------

Refractory anaphylaxis was most commonly elicited by drugs (significantly more often than in severe, non-refractory cases), followed by food and insects ([Table 2](#T2){ref-type="table"}). The most common drugs eliciting anaphylaxis refractory to adrenaline were antibiotics (19%) and radiocontrast media (RCM, 7.14%). Patients with refractory anaphylaxis more frequently experienced the reaction while undergoing a medical procedure (54.8% vs. 12.3 in severe, non-refractory cases, *p* \< 0.0001).

###### 

Summary of elicitors in the refractory anaphylaxis cases and severe, non-refractory anaphylaxis cases as a control.

  **Elicitor**   ***n***   **%**   **% severe ANA**   **Perioperative \[*n*\]**   **Food allergy \[*n*\]**   **Age**   **Male \[%\]**   ***p***
  -------------- --------- ------- ------------------ --------------------------- -------------------------- --------- ---------------- ---------
  Food           9         21.4    24.1               0                           3                          17.4      55.6             0.8560
  Drugs          21        50.0    19.7               19                          0                          48.8      42.9             0.0001
  Insects        8         19.0    48.1               0                           0                          46.5      62.5             0.0001
  Other          2         4.8     3.0                0                           1                          38.0      0.0              0.3610
  Unknown        2         4.8     5.1                0                           0                          55.5      50.0             0.0001

*ANA, anaphylaxis, age is represented as a mean, p-value derived from the Fisher\'s exact test*.

Thirty three percent of food elicited refractory cases had a previously confirmed diagnosis of food allergy. Insect-venom and food allergens most frequently elicited severe cases of anaphylaxis. Refractory anaphylaxis cases were more often elicited by bees than severe, non-refractory cases, *p* = 0.0092 ([Table 3](#T3){ref-type="table"}).

###### 

Comparison of the specific elicitors from each elicitor-group between the refractory anaphylaxis cases and severe anaphylaxis cases as a control.

  **Elicitor**          **Severe ANA \[%\]**   **Refractory ANA \[%\]**   ***p*-value**
  --------------------- ---------------------- -------------------------- ---------------
  Antibiotics           6.140                  19.00                      0.0040
  X-ray medium          0.954                  7.14                       0.0080
  Muscle relaxant       0.456                  4.76                       0.0180
  Legumes               4.020                  7.14                       0.2410
  Bee venom             9.320                  11.90                      0.5890
  Yellow-jacket venom   33.300                 4.76                       0.0001

*ANA, anaphylaxis, p-value derived from the Fisher\'s exact test*.

Refractory Anaphylaxis Is Life-Threatening
------------------------------------------

Milder anaphylaxis symptoms (i.e., pruritus, gastrointestinal symptoms, vertigo, chest, and throat tightness) were significantly less present in refractory anaphylaxis cases, whereas respiratory and cardiac arrest, as well as inspiratory and expiratory distress, and death were more often associated with the refractory anaphylaxis cases. [Table 4](#T4){ref-type="table"} summarizes the most prominent differences in anaphylaxis symptoms among both groups. Fatal reactions frequently occurred 30--120 min after allergen exposure and were highly associated with refractory cases (26.2% vs. only 0.353% of severe anaphylaxis cases, *p* \< 0.0001) In cases where patients responded to life support, but failed to be reanimated due to post-resuscitative complication (e.g., hypoxic brain injury), death occurred in the next 3--8 days.

###### 

Summary of the symptoms in the refractory anaphylaxis cases and severe, non-refractory anaphylaxis cases as a control.

  **Symptom**             **Severe ANA \[%\]**   **Refractory ANA \[%\]**   ***p*-value**
  ----------------------- ---------------------- -------------------------- ---------------
  Pruritus                45.40                  23.80                      0.0050
  Skin symptoms           44.80                  26.20                      0.0190
  Respiratory symptoms    62.10                  81.00                      0.0150
  Respiratory arrest      3.03                   28.60                      0.0001
  Chest tightness         8.90                   2.38                       0.1760
  Throat tightness        14.60                  7.14                       0.2680
  Expiratory distress     5.08                   26.20                      0.0001
  Inspiratory stridor     5.31                   19.00                      0.0020
  Loss of consciousness   31.90                  40.50                      0.2470
  Cardiac arrhythmia      3.30                   11.90                      0.0130
  Cardiac arrest          3.07                   42.90                      0.0001
  Vertigo                 38.70                  14.30                      0.0001
  Death                   0.35                   26.20                      0.0001

*ANA, anaphylaxis, p-value derived from the Fisher\'s exact test*.

Adrenaline i.v. as First-Line Treatment Was Given Frequently in Refractory Anaphylaxis
--------------------------------------------------------------------------------------

When evaluating the therapeutic procedures, adrenaline i.v. as a first-line treatment of anaphylaxis was significantly more often given in refractory cases (83.3% vs. 16.7%, *p* \< 0.0001). Median time to the second dose of adrenaline was also shorter in refractory cases (2 vs. 15 min in non-refractory cases, *p* \< 0.0001).

Corticosteroids i.v. were the second most frequently administered group of drugs in refractory cases (as a first and second-line treatment), outpacing antihistaminic drugs, and volume replacement therapy, and were significantly more often given in refractory cases. Volume replacement therapy was given initially in 61.9% of refractory cases and was sustained only in 19% as the therapy progressed in the hospital environment.

Second-line medication like dopamine, glucagon, and methylene blue were not given in all refractory anaphylaxis cases as well as in severe non-refractory ones. However, patients with refractory anaphylaxis were more frequently admitted to the hospital (85.7%) and treated at the ICUs (78.6%). [Table 5](#T5){ref-type="table"} illustrates the therapy of refractory anaphylaxis cases.

###### 

Summary of therapeutic measures in the refractory anaphylaxis cases and severe, non-refractory anaphylaxis cases as a control.

  **Therapy**                     **Severe ANA \[%\]**   **Refractory ANA \[%\]**   ***p*-value**
  ------------------------------- ---------------------- -------------------------- ---------------
  Adrenaline i.m.                 8.38                   16.70                      0.0840
  Adrenaline i.v.                 12.30                  83.30                      0.0001
  Adrenaline i.v. 2nd line        0.73                   40.50                      0.0001
  Volume                          20.50                  61.90                      0.0001
  Volume, 2nd line                3.34                   19.00                      0.0001
  Antihistaminics i.v.            40.90                  64.30                      0.0030
  Antihistaminics i.v. 2nd line   3.84                   21.40                      0.0001
  Corticosteroids, all routes     5.52                   7.14                       0.5040
  Corticosteroids i.v.            48.80                  73.80                      0.0020
  Corticosteroids i.v. 2nd line   5.37                   28.60                      0.0001
  Beta-2-mimetics i.v.            0.66                   2.38                       0.2500
  Beta-2-mimetics inh. 2nd line   0.75                   7.14                       0.0040
  Theophylline i.v.               0.42                   0.00                       1.0000
  100% oxygen                     9.42                   47.60                      0.0001
  Dopamine i.v.                   0.04                   0.00                       1.0000
  Glucagon i.v.                   0.02                   0.00                       1.0000
  Methylene blue                  0.00                   0.00                       1.0000
  Hospital admission              28.00                  85.70                      0.0001
  Intensive care                  7.55                   78.60                      0.0001

"*2nd line" refers to the therapy performed by the professional medical emergency team after the initial rescue procedures. ANA, anaphylaxis, p-value derived from the Fisher\'s exact test*.

Cofactors of Refractory Anaphylaxis
-----------------------------------

Patients with refractory anaphylaxis more often had concomitant asthma and malignant diseases in their medical history. Also, other unspecified concomitant conditions were significantly more often reported in refractory cases. Concomitant cardiologic conditions, diabetes, and mastocytosis were similarly frequent in both groups.

Patients with refractory anaphylaxis more often reported concomitant intake of proton pump inhibitors (PPI) and acetylsalicilic acid (ASA) compared with patients with severe non-refractory anaphylaxis. Other (not specified) medications were also more frequent in refractory cases. In 6 cases of refractory anaphylaxis (14.3%) patients reported receiving beta-blockers as a concomitant medication, but none of these patients received a glucagon infusion.

The intensity of physical exercise exceeding the reaction was indifferent between groups, however psychological burden (defined as a stressful event preceding the reaction, rated by the physician) was reported three times more frequently in refractory cases (see [Table 6](#T6){ref-type="table"}).

###### 

Factors potentially increasing the risk of a severe anaphylaxis investigated in refractory cases.

  **Factor**                                **Severe ANA \[%\]**   **Refractory ANA \[%\]**   ***p*-value**
  ----------------------------------------- ---------------------- -------------------------- ---------------
  Concomitant asthma                        12.10                  29.30                      0.0030
  Concomitant AD                            6.82                   12.20                      0.2000
  Concomitant diabetes                      5.80                   13.20                      0.0700
  Concomitant cardiologic condition         22.80                  31.70                      0.1910
  Concomitant infection                     3.35                   4.88                       0.6480
  History of malignant disease              3.12                   10.80                      0.0290
  Concomitant mastocytosis                  2.68                   7.32                       0.0990
  Concomitant other disease---unspecified   15.60                  36.60                      0.0001
  Exercise prior to reaction                28.10                  21.40                      0.3920
  Psychological burden                      6.79                   26.20                      0.0001
  Concomitant medication                    37.50                  60.50                      0.0060
  ASA                                       6.13                   18.40                      0.0080
  Beta-blockers                             10.40                  15.80                      0.2810
  PPI                                       5.81                   20.60                      0.0030
  Other drugs                               18.20                  44.70                      0.0001
  Alcohol use prior to the reaction         5.51                   2.63                       0.7210

*ANA, anaphylaxis, p-value derived from the Fisher\'s exact test*.

Discussion {#s4}
==========

Frequency of Refractory Anaphylaxis and Patients at Risk
--------------------------------------------------------

Our findings suggest that around 1 in 100 severe anaphylaxis patients will not respond to the standard therapy with adrenaline, commonly outlined in anaphylaxis management guidelines ([@B8]). Such cases have the highest risk of a fatal outcome, and therefore need to be treated accordingly. Early use of adrenaline and maybe other second-line drugs (e.g., methylene blue and dopamine) might increase their survival chance.

Overall, the severity of anaphylaxis and its probable transition into a refractory episode might depend on several co-influencing mechanisms: (1) elicitors---the type and dose of an eliciting agent and route of exposure; (2) cofactors---the presence of other individual and external factors which may increase the severity of a given reaction, e.g., concomitant use of a beta-blocker; (3) compensation---how well the affected individual can compensate reaction symptoms, e.g., hypotension; (4) therapy---how fast and accurately the therapeutic interventions were applied ([Figure 2](#F2){ref-type="fig"}).

![Visual representation of the three forces determining the severity of anaphylaxis. The natural ability of the body to compensate for the anaphylaxis symptoms and therapeutic measures acting to restore homeostasis. Elicitors and cofactors influence the severity of a given episode synergistically.](fimmu-10-02482-g0002){#F2}

Elicitors
---------

Drugs were the most commonly occurring elicitor, which is in concordance with the literature and our previous findings ([@B4]). Multiple medications with mast cell activation potential ([@B9]) given in a perioperative setting increase the chance of a hypersensitivity reaction and drug interactions ([@B10]). A recent study on IgE-independent anaphylaxis showed that perioperative drugs (i.e., rocuronium, tubocurarine, fluoroquinolones, atracurium) might trigger anaphylaxis by activating mast cells directly through the MRGPRX2 receptor ([@B11]). Therefore, patients undergoing surgical procedures and having a history of anaphylaxis should remain under extraordinary caution.

Antibiotics, although commonly triggering IgE-dependent reactions ([@B12]), are rarely reported in the literature as the cause of refractory anaphylaxis. RCM, on the other hand, commonly elicit IgE-independent hypersensitivity episodes that are refractory to adrenaline and are responsible for 1--5 deaths per 100,000 administrations ([@B13]). We previously reported RCM to be the most frequent elicitor of refractory anaphylaxis ([@B4]). It might be that RCM promotes complement activation ([@B14]) and thus---unspecific activation of multiple immune cell classes (mast cells, basophils, platelets, and neutrophils). Therefore, treatment with adrenaline may be less effective in these reactions.

Yellow-jacket-stings elicited only a few refractory cases. Therefore, the ratio of yellow-jacket to honey-bee venom elicited anaphylaxis was inverted in the refractory group. Reasons for this observation might include higher allergen exposition due to either extended exposition to the allergen (bee\'s sting remains in the skin) or the venom volume being 10 times higher than in a wasp sting ([@B15]).

Risk Factors
------------

Although we have previously identified higher age and male sex to be associated with severe anaphylaxis ([@B6]), these factors seem to be less critical in refractory anaphylaxis cases. By contrast, we previously associated concomitant asthma with less severe anaphylaxis in our registry data ([@B6]). However, the present analysis, as well as other previous data ([@B16]), suggest concomitant asthma as a risk factor for a severe episode. Probably the control of the asthmatic condition is essential in this context and should be therefore evaluated in patients at risk. Moreover, it might be possible that during a refractory episode the bronchospasm is additionally triggered via mediators derived from basophils and eosinophils or the vegetative nerve system what makes it refractory to adrenaline and results in a prolonged anaphylactic episode. Accordingly, we observed more respiratory distress symptoms in the refractory anaphylaxis cases.

Baseline serum tryptase (BST) levels were increased in patients with refractory anaphylaxis, although only in 7 patients they exceeded the threshold level of 11.5 ng/mL---what is commonly recognized as elevated ([@B17]). BST may reflect pro-β tryptase due to increased body mast cell content ([@B18]) or result from alpha-tryptasemia due to multiple copies of *TPSAB1* gene ([@B19]). Irrespective of the mechanism---increased BST has been shown to correlate with the severity of anaphylaxis ([@B20]).

The higher rate of malignancy in patients with refractory anaphylaxis diseases might be a confounder as certain intravenous chemotherapeutics are well known to directly activate mast cells (e.g., taxanes) ([@B21]). On the other hand, it is possible that patients with reported malignancies were older (mean age of 34.6 vs. 58.3 years, *p* \< 0.001) and therefore less able to compensate the anaphylactic shock.

Psychological stress in temporal proximity to the reaction might increase the severity of the reaction as we previously reported ([@B6]). Stress induces the complement cascade activation ([@B22]). Substance P, released during stress ([@B23]), is a known vasodilator ([@B24]) and can activate mast cells directly ([@B25]). These mediators may contribute to an increased mast cell response and more severe anaphylaxis. Some published case reports indicated stressful event as the anaphylaxis trigger ([@B26]).

Wölbling et al. indicated the role of PPI as a risk factor for severe anaphylaxis by prolonging the exposition to an oral allergen (preventing its degradation due to lower gastric acid production) ([@B27]). Moreover, there are reports on PPI themselves as elicitors of anaphylaxis ([@B28]). We observed a significantly higher rate of PPI intake in the refractory anaphylaxis group. Its mechanistic contribution to the increase in severity of an episode or being responsible for its refractoriness cannot be estimated based on this observation.

Concomitant ASA use was also associated with refractory cases more frequently than in severe anaphylaxis. The role of ASA on increasing the severity of anaphylaxis has previously been implicated by increasing the intestinal absorption of allergens ([@B27]). Nevertheless, as ASA might be both a cofactor and elicitor of anaphylaxis ([@B29]) and is highly correlated with another cofactor---concomitant cardiologic conditions---it is tough to evaluate its isolated influence on the anaphylaxis severity.

Symptom Compensation
--------------------

Age is the most critical factor influencing the risk of developing severe anaphylaxis ([@B6]). We and others have shown that older age may correlate with the decreased ability to retain homeostasis on increased strain ([@B30]). Patients who underwent refractory anaphylaxis more often had perioperative reactions and therefore, a decreased ability to compensate the reaction symptoms with reflexive renal or cardiopulmonary response ([@B31]).

Compensation mechanisms demonstrated in animal models indicated that anaphylactic hypotension activates the hypothalamic paraventricular nucleus, medullary nucleus tractus solitarii, and rostral ventrolateral medulla, independently of the baroreflex pathway. Further, it stimulates efferent sympathetic nerve activity to the adrenal gland and kidney to restore blood pressure ([@B32]).

Therapy
-------

Physicians and surgeons often used adrenaline i.v. as first-line therapy in refractory cases, probably because most of them occurred in a medical setting. However, other second-line therapeutic options were rarely used. Grabenhenrich et al. ([@B2]) recently evaluated the epinephrine usage in anaphylaxis patients and concluded that, even in this state of the art drug, significant discrepancies between recommended use and actual treatment practice exist. Similarly, US studies documented poor adherence in patients and caregivers to anaphylaxis guidelines recommending more than one adrenaline autoinjector available at all times ([@B33]). Therefore, more effort needs to be dedicated to promote and develop consensus guidelines as practically as possible in order to increase adherence.

Methylene blue and vasopressors have been described to successfully restore refractory hypotension and recommended by management guidelines ([@B8]), but their actual use in anaphylaxis patients is scarce. There are multiple reports of successful methylene blue use in refractory anaphylaxis ([@B4]). Evora ([@B34]) reported 6 cases of refractory, perioperative anaphylaxis (to RCM and penicillin) which responded to methylene blue i.v. within minutes. Methylene blue blocks the guanylate cyclase and therefore prevents further nitric-oxide-dependent vasodilation in a distributive shock ([@B35]). Its potential role in neuroprotection has also been indicated ([@B36]).

Surprisingly, even though multiple anaphylaxis management guidelines recommend glucagon infusions in cases of concomitant beta-blocker therapy in anaphylactic patients ([@B8], [@B37], [@B38]), it has not been administered in any of the severe or refractory cases. Similarly, Royal Collage of Anesthetists reported one glucagon administration in 266 severe intraoperative anaphylaxis episodes ([@B39]). Glucagon has been reported to successfully relive refractory anaphylaxis ([@B40], [@B41]) by directly activating the adenylyl cyclase and therefore bypassing the β-adrenergic receptor blockade ([@B40]).

Limitations and Strengths
-------------------------

The low number of refractory cases prevented us from analyzing the data with more advanced statistical models. However, our analysis is the first report on a patient cohort exceeding 30 refractory anaphylaxis cases.

The definition of refractory anaphylaxis is not universal, and we had to assume it based on the answers to our online questionnaire. If a fatal reaction occurred before the second dose of adrenaline was administered to the patient (although, it might have been refractory)---it was not categorized as refractory as we defined at least two doses of minimum 300 μg adrenaline for refractory anaphylaxis.

The therapy with adrenaline was not weight-adapted, and patients received multiple fixed doses of adrenaline ranging from 300 to 1,000 μg. It is possible that patients experiencing anaphylaxis refractory to standard doses of adrenaline were treated with subtherapeutic doses in the initial phase of the reaction due to their obesity. However, we did not gather data on the patient\'s weight, and therefore, we cannot conclude how it influenced the therapy-outcomes with fixed doses of adrenaline. Nevertheless, repeated doses of adrenaline should be sufficient to alleviate the symptoms in such patients if the weight would be the only reason for the refractoriness of anaphylaxis.

The comparison of refractory anaphylaxis with patients suffering from severe anaphylaxis enabled us to distinguish patients with a higher risk of developing a refractory episode. However, we cannot address the question which patients had a higher risk of experiencing anaphylaxis per se.

Conclusion {#s5}
==========

Refractory anaphylaxis is a rare form of a life-threatening hypersensitivity reaction with high mortality. Its elicitors and cofactors differ from other anaphylaxis cases, and the management of refractory anaphylaxis needs to improve. Although, more studies need to be conducted to understand better the pathomechanisms involved in refractory anaphylaxis, we propose to increase the use of second-line medication such as methylene blue, vasopressin and (in suspicion of a beta-adrenergic blockade) glucagon in cases where 2 doses of adrenaline did not result in a rapid normalization of anaphylaxis symptoms.
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